Article
Medicine, General & Internal
Heather Wakelee, Moishe Liberman, Terufumi Kato, Masahiro Tsuboi, Se-Hoon Lee, Shugeng Gao, Ke-Neng Chen, Christophe Dooms, Margarita Majem, Ekkehard Eigendorff, Gaston L. Martinengo, Olivier Bylicki, Delvys Rodriguez-Abreu, Jamie E. E. Chaft, Silvia Novello, Jing Yang, Steven M. M. Keller, Ayman Samkari, Jonathan D. D. Spicer
Summary: Among patients with resectable early-stage NSCLC, perioperative pembrolizumab improved event-free survival, major pathological response, and pathological complete response. The addition of pembrolizumab to neoadjuvant chemotherapy followed by surgery showed significant benefits compared to neoadjuvant chemotherapy alone followed by surgery.
NEW ENGLAND JOURNAL OF MEDICINE
(2023)
Article
Computer Science, Artificial Intelligence
Siamak Kheybari
Summary: This paper proposes a new approach based on defining upper and lower expectation levels for each decision-making criterion to address the trade-offs in multi-criteria decision-making problems.
INTERNATIONAL JOURNAL OF INFORMATION TECHNOLOGY & DECISION MAKING
(2021)
Review
Oncology
Stephanie P. L. Saw, Boon-Hean Ong, Kevin L. M. Chua, Angela Takano, Daniel S. W. Tan
Summary: Despite the advancements in treatment for advanced non-small-cell lung cancer (NSCLC), there is a renewed interest in neoadjuvant strategies for early-stage NSCLC. These strategies, including targeted therapy and immunotherapy, have the potential to greatly impact survival outcomes for early-stage NSCLC patients.
Article
Health Care Sciences & Services
Ronald E. Myers, Shailesh M. Advani, Pamela Myers, Preethi Selvan, Gregory Garber, Brooke Worster, Neal Flomenberg, Andrew Chapman, Ralph Zinner
Summary: This study developed a novel DSI to assist NSCLC patients in treatment shared decision making, which was found to increase patient awareness of treatment options and decrease concern about treatment costs. Additional randomized controlled trials are needed to further evaluate the feasibility and efficacy of DSI implementation in clinical care.
JOURNAL OF PERSONALIZED MEDICINE
(2021)
Article
Medicine, General & Internal
John V. Heymach, David Harpole, Tetsuya Mitsudomi, Janis M. Taube, Gabriella Galffy, Maximilian Hochmair, Thomas Winder, Ruslan Zukov, Gabriel Garbaos, Shugeng Gao, Hiroaki Kuroda, Gyula Ostoros, Tho V. Tran, Jian You, Kang-Yun Lee, Lorenzo Antonuzzo, Zsolt Papai-Szekely, Hiroaki Akamatsu, Bivas Biswas, Alexander Spira, Jeffrey Crawford, Ha T. Le, Mike Aperghis, Gary J. Doherty, Helen Mann, Tamer M. Fouad, Martin Reck, AEGEAN Invest
Summary: In resectable non-small-cell lung cancer patients, perioperative durvalumab plus neoadjuvant chemotherapy showed significantly improved event-free survival and pathological complete response compared to neoadjuvant chemotherapy alone, with a similar safety profile.
NEW ENGLAND JOURNAL OF MEDICINE
(2023)
Article
Medicine, General & Internal
Mariano Provencio, Ernest Nadal, Jose L. Gonzalez-Larriba, Alex Martinez-Marti, Reyes Bernabe, Joaquim Bosch-Barrera, Joaquin Casal-Rubio, Virginia Calvo, Amelia Insa, Santiago Ponce, Noemi Reguart, Javier de Castro, Joaquin Mosquera, Manuel Cobo, Andres Aguilar, Guillermo Lopez Vivanco, Carlos Camps, Rafael Lopez-Castro, Teresa Moran, Isidoro Barneto, Delvys Rodriguez-Abreu, Roberto Serna-Blasco, Raquel Benitez, Carlos Aguado de la Rosa, Ramon Palmero, Florentino Hernando-Trancho, Javier Martin-Lopez, Alberto Cruz-Bermudez, Bartomeu Massuti, Atocha Romero
Summary: This study evaluated the efficacy of the neoadjuvant nivolumab plus chemotherapy regimen on operable stage III non-small-cell lung cancer (NSCLC) patients. The results showed that patients receiving the combination therapy had a higher rate of pathological complete response and longer survival, indicating the effectiveness of this treatment approach in this patient population.
NEW ENGLAND JOURNAL OF MEDICINE
(2023)
Review
Oncology
Jatta Saarenheimo, Heidi Andersen, Natalja Eigeliene, Antti Jekunen
Summary: Decision-making in cancer treatment, especially in NSCLC patients, heavily relies on gene alterations, with early molecular testing of liquid biopsy samples showing increased sensitivity in detecting targetable mutations. Efforts are needed for logistics of obtaining and evaluating samples, and tissue samples should be saved for tests that are not possible from liquid biopsy.
FRONTIERS IN ONCOLOGY
(2021)
Article
Engineering, Civil
Xiaokuan Ni, Zengchuan Dong, Yong Jiang, Wei Xie, Hongyi Yao, Mufeng Chen
Summary: This paper introduces a preference decision method (PDM) based on Pareto solutions, which quantifies the complex internal feedback relationship among various targets, providing objective support for decision-makers in the subjective trade-offs of the interests of multiple subjects and achieving the unity of subjective and objective.
JOURNAL OF HYDROLOGY
(2022)
Review
Oncology
Martin Reck, Jordi Remon, Matthew D. Hellmann
Summary: The past decade has seen significant progress in the treatment of metastatic non-small-cell lung cancer, with the development of specific antibodies leading to improved survival for many patients. Currently, nearly all mNSCLC patients receive PD-1 or PD-L1 therapy in the first-line setting, except those with targetable oncogenes.
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Review
Oncology
Qianqian Guo, Liwei Liu, Zelong Chen, Yannan Fan, Yang Zhou, Ziqiao Yuan, Wenzhou Zhang
Summary: Despite advancements in diagnosis and treatment, lung cancer mortality remains high. This review provides an overview of current diagnostic methods and therapies for non-small cell lung cancer, serving as a guide for clinicians.
FRONTIERS IN ONCOLOGY
(2022)
Article
Medicine, General & Internal
Bob T. Li, Egbert F. Smit, Yasushi Goto, Kazuhiko Nakagawa, Hibiki Udagawa, Julien Mazieres, Misako Nagasaka, Lyudmila Bazhenova, Andreas N. Saltos, Enriqueta Felip, Jose M. Pacheco, Maurice Perol, Luis Paz-Ares, Kapil Saxena, Ryota Shiga, Yingkai Cheng, Suddhasatta Acharyya, Patrik Vitazka, Javad Shahidi, David Planchard, Pasi A. Janne
Summary: Trastuzumab deruxtecan demonstrated durable anticancer activity in previously treated HER2-mutant NSCLC patients, with two cases of fatal drug-related interstitial lung disease reported. The observed toxic effects were generally consistent with previous studies.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Review
Pharmacology & Pharmacy
Zaid Sirhan, Rawan Alojair, Anita Thyagarajan, Ravi P. Sahu
Summary: Lung cancer is a major malignancy globally, with NSCLC being the most common type. PTEN, a tumor suppressor gene, plays a critical role in regulating cancer growth and its dysfunction is associated with poor prognosis in lung cancer patients. PTEN has been explored as a promising target for anti-cancer agents, as it can interact with multiple signaling pathways to devise effective treatment options for NSCLC.
Review
Medicine, Research & Experimental
Zhencong Ye, Yongmei Huang, Jianhao Ke, Xiao Zhu, Shuilong Leng, Hui Luo
Summary: Non-small cell lung cancer (NSCLC) is the most common and deadly malignancy of lung cancer; chemotherapy is gradually withdrawn from the stage of history due to its obvious side effects; researchers are now focusing on targeted drugs for the treatment.
BIOMEDICINE & PHARMACOTHERAPY
(2021)
Article
Health Care Sciences & Services
Chawalit Chayangsu, Jiraporn Khorana, Chaiyut Charoentum, Virote Sriuranpong, Jayanton Patumanond, Apichat Tantraworasin
Summary: A clinical prediction score (CPS) was developed to predict the response of advanced non-small cell lung cancer patients after chemotherapy, which could be useful for patient selection and risk communication. This score is based on six clinical parameters and showed a high probability for chemotherapy response in the first-line setting.
Editorial Material
Oncology
Yu Chen, Jinming Yu, Xiangjiao Meng
Summary: This commentary emphasizes the potential of postoperative radiotherapy in patients with completely resected IIIA-N2 non-small cell lung cancer.
Article
Urology & Nephrology
Dickon Hayne, Jeremy Grummet, David Espinoza, Steve P. McCombie, Venu Chalasani, Kate S. Ford, Mark Frydenberg, Peter Gilling, Barbara Gordon, Cynthia Hawks, Alex Konstantatos, Andrew J. Martin, Anthony Nixon, Colin O'Brien, Manish Patel, Shomik Sengupta, Shekib Shahbaz, Shalini Subramaniam, Scott Williams, Henry H. Woo, Martin R. Stockler, Ian D. Davis, Nick Buchan
Summary: The study found that the addition of inhaled methoxyflurane did not improve pain scores at 15 min after TRUSB, but it did lead to improvements in patient-reported discomfort, overall experience, and willingness to undergo repeat biopsies.
Article
Oncology
Ann Livingstone, Kathy Dempsey, Martin R. Stockler, Kirsten Howard, Georgina Long, Matteo S. Carlino, Alexander M. Menzies, Rachael L. Morton
Summary: This study explored factors considered by physicians and nurses regarding adjuvant immunotherapy for melanoma, identifying three themes in recommendations: clinical and patient factors, treatment information provision, and individual physician/nurse factors. The primary considerations for recommending immunotherapy were melanoma sub-stage and the patient's therapy risk/benefit profile.
Review
Health Care Sciences & Services
Rebecca Mercieca-Bebber, Sayeda Kamrun Naher, Orlando Rincones, Allan Ben Smith, Martin R. Stockler
Summary: The treatment of testicular cancer has long-term and dose-dependent impacts on health-related quality of life and functional outcomes. Chemotherapy has a higher burden of side effects compared to other treatments, particularly at higher doses.
PATIENT-RELATED OUTCOME MEASURES
(2021)
Article
Oncology
Martin R. Stockler, Andrew J. Martin, Ian D. Davis, Haryana M. Dhillon, Stephen D. Begbie, Kim N. Chi, Simon Chowdhury, Xanthi Coskinas, Mark Frydenberg, Wendy E. Hague, Lisa G. Horvath, Anthony M. Joshua, Nicola J. Lawrence, Gavin M. Marx, John McCaffrey, Ray McDermott, Margaret McJannett, Scott A. North, Francis Parnis, Wendy R. Parulekar, David W. Pook, M. Neil Reaume, Shahneen Sandhu, Alvin Tan, Thean Hsiang Tan, Alastair Thomson, Francisco Vera-Badillo, Scott G. Williams, Diana G. Winter, Sonia Yip, Alison Y. Zhang, Robert R. Zielinski, Christopher J. Sweeney
Summary: Enzalutamide improves overall survival in metastatic, hormone-sensitive prostate cancer, but has limited effects on health-related quality of life.
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Article
Oncology
Rhonda Farrell, Michael Burling, Yeh Chen Lee, Selvan Pather, Kristy Robledo, Rebecca Mercieca-Bebber, Martin Stockler
Summary: This study aims to compare the safety and effectiveness of hyperthermic intraperitoneal chemotherapy (HIPEC) and normothermic intraperitoneal chemotherapy (NIPEC) in the treatment of ovarian cancer. The study hypothesizes that NIPEC will result in a lower rate of severe adverse events. It is a multi-stage randomized study that includes assessment of safety, activity, effectiveness, and potential predictive biomarkers.
JOURNAL OF GYNECOLOGIC ONCOLOGY
(2022)
Article
Medicine, General & Internal
Peey Sei Kok, Patrick M. Forde, Brett Hughes, Zhuoxin Sun, Chris Brown, Suresh Ramalingam, Alistair Cook, Willem Joost Lesterhuis, Sonia Yip, Ken O'Byrne, Nick Pavlakis, Julie Brahmer, Valsamo Anagnostou, Kate Ford, Karen Fitzpatrick, Alison Bricker, Michelle M. Cummins, Martin Stockler, Anna K. Nowak
Summary: The DREAM3R trial aims to assess the efficacy of combining PD-L1 inhibitor durvalumab with first-line chemotherapy in pleural mesothelioma. This multicentre, open-label randomized trial will recruit 480 treatment-naive patients and evaluate various endpoints, including overall survival and adverse events.
Letter
Oncology
Martin R. Stockler, Andrew J. Martin, Haryana M. Dhillon, Ian D. Davis, Christopher J. Sweeney
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Article
Oncology
Bhavna Oza, Tim Eisen, Eleni Frangou, Grant D. Stewart, Axel Bex, Alastair W. S. Ritchie, Rick Kaplan, Benjamin Smith, Ian D. Davis, Martin R. Stockler, Laurence Albiges, Bernard Escudier, James Larkin, Steven Joniau, Barry Hancock, Gregers G. Hermann, Joaquim Bellmunt, Mahesh K. B. Parmar, Patrick Royston, Angela Meade
Summary: This study provides a robust external validation of the 2003 Leibovich score using contemporary data, demonstrating its discriminative accuracy and calibration in predicting risk for patients with locally advanced renal cell carcinoma (RCC). The score can be used to guide risk stratification in adjuvant clinical trials for RCC patients.
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Article
Oncology
Blossom Mak, Hui-Ming Lin, Thy Duong, Kate L. Mahon, Anthony M. Joshua, Martin R. Stockler, Howard Gurney, Francis Parnis, Alison Zhang, Tahlia Scheinberg, Gary Wittert, Lisa M. Butler, David Sullivan, Andrew J. Hoy, Peter J. Meikle, Lisa G. Horvath
Summary: This study found that simvastatin can modify the poor lipid profile in men with metastatic castration-resistant prostate cancer (mCRPC). Higher levels of sphingolipids, which are associated with poor prognosis, were reduced after simvastatin treatment. These findings are important for improving overall survival and therapeutic outcomes in mCRPC patients.
Article
Health Care Sciences & Services
Rachel Campbell, Madeleine T. King, Martin R. Stockler, Yeh Chen Lee, Felicia T. Roncolato, Michael L. Friedlander
Summary: Patient-reported outcomes (PROs) are important in assessing symptoms and treatment effects in ovarian cancer. Well-validated PRO measures can be used in clinical trials to guide improvements in clinical practice and health policy. In clinical practice, PRO assessments can help monitor symptoms and facilitate communication between patients and their clinicians.
PATIENT-RELATED OUTCOME MEASURES
(2023)
Article
Health Care Sciences & Services
Ann Livingstone, Kirsten Howard, Alexander M. Menzies, Georgina V. Long, Martin R. Stockler, Rachael L. Morton
Summary: This study aimed to quantify adult preferences for adjuvant immunotherapy for resected melanoma and the influence of varying levels of key attributes and baseline characteristics. The study found that 70% of respondents chose adjuvant immunotherapy over no adjuvant immunotherapy, preferring treatment that improved efficacy and safety. The importance of this study is rated 8 out of 10.
PATIENT-PATIENT CENTERED OUTCOMES RESEARCH
(2023)
Meeting Abstract
Oncology
Danka Zebic, Martin Stockler, Andrew Martin, Farzana Pashankar, Ben Tran, Danish Mazhar, Robert Huddart, Matthew Wheater, Euan Walpole, Elaine Dunwoodie, Darren Feldman, Alison Birtle, Amanda Stevanovic, David Wyld, Fritha Hanning, Peter Grimison
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY
(2022)
Meeting Abstract
Oncology
Sharon Nahm, Andrew Martin, Martin Stockler, Belinda Kiely
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY
(2022)
Meeting Abstract
Radiology, Nuclear Medicine & Medical Imaging
J. Buteau, A. Martin, L. Emmett, A. Iravani, S. Sandhu, A. M. Joshua, R. J. Francis, A. Y. Zhang, A. M. Scott, S. Lee, A. Azad, M. McJannett, M. R. Stockler, S. Williams, I. D. Davis, M. S. Hofman
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
(2022)
Article
Health Care Sciences & Services
Ann Livingstone, Donna Milne, Kathy Dempsey, Danielle Marie Muscat, Alexander M. Menzies, Kirsten Howard, Martin R. Stockler, Rachael L. Morton
Summary: The study explored the views of melanoma patients and their partners when considering adjuvant immunotherapy. Findings showed that prolonging life was the primary consideration, followed by concerns about treatment burden, timing, costs, and efficacy.
PATIENT-PATIENT CENTERED OUTCOMES RESEARCH
(2021)